INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 22 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $3,118,000 | 0.0% | 5,175,000 | 0.0% | 0.07% | +7.4% |
| Q4 2021 | $3,118,000 | -75.8% | 5,175,000 | -74.2% | 0.07% | -86.7% |
| Q1 2021 | $12,862,000 | -63.0% | 20,093,000 | -64.1% | 0.51% | -61.4% |
| Q4 2020 | $34,742,000 | -11.1% | 55,943,000 | 0.0% | 1.33% | -36.8% |
| Q3 2020 | $39,071,000 | +93.0% | 55,943,000 | +100.2% | 2.11% | +22.3% |
| Q2 2020 | $20,241,000 | +24.2% | 27,943,000 | +55.2% | 1.72% | -27.6% |
| Q3 2019 | $16,303,000 | -18.1% | 18,000,000 | -10.0% | 2.38% | +80.9% |
| Q2 2019 | $19,894,000 | – | 20,000,000 | – | 1.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
| PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
| Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
| Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
| Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
| Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
| Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
| CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |